Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Launched by POWER LIFE SCIENCES INC. · Sep 30, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the experiences of patients with recurrent prostate cancer. Researchers want to find out how new treatments compare to traditional ones in terms of safety and effectiveness. By gathering and analyzing information from different groups of patients, they hope to identify patterns that can help improve future care for others facing this diagnosis.
To take part in the trial, participants need to be at least 18 years old and have been diagnosed with recurrent prostate cancer. They must also be able to understand the study and agree to participate by signing a consent form. However, those already involved in another research study or who have certain psychiatric conditions that might affect their ability to follow the study's requirements will not be eligible. If you join, you can expect to contribute valuable information that could lead to better treatments for prostate cancer in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patient is at least 18 years of age
- • Diagnosis of recurrent prostate cancer
- • Ability to understand and the willingness to sign a written informed consent document
- Exclusion Criteria:
- • Enrolled in another research study
- • Patients with psychiatric illness/social situations that would limit compliance with study requirements
- • Inability to provide written informed consent
About Power Life Sciences Inc.
Power Life Sciences Inc. is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapeutic solutions across various medical disciplines. With a strong emphasis on scientific rigor and patient-centered approaches, the organization collaborates with leading researchers and healthcare professionals to design and execute clinical trials that prioritize safety, efficacy, and compliance. Power Life Sciences Inc. leverages cutting-edge technology and data analytics to streamline trial processes, enhance participant engagement, and accelerate the development of life-changing treatments, ultimately aiming to improve patient outcomes and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Michael B Gill
Study Director
Power Life Sciences Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported